M&A Deal Summary
|Sellers(s)||EW Healthcare Partners|
|Deal Type||Add-on Acquisition|
|Deal Value||75M EUR|
Try For Free 7-Day Free Trial
|Revenue||348M EUR (2021)|
Valneva is a biotechnology company which focuses on the development of modern prophylactic and therapeutic vaccines against infectious diseases. Valneva is based in Saint-Herblain, France.
|Overall||1 of 2|
|Sector (Medical Products)||1 of 1|
|Type (Add-on Acquisition)||1 of 1|
|State (Pennsylvania)||1 of 1|
|Country (United States)||1 of 1|
|Year (2008)||1 of 1|
Vivalis is a biopharmaceutical company that provides innovative cell-based solutions to the biotechnology and pharmaceutical industry for the manufacture of vaccines and recombinant proteins, and develops monoclonal antibodies for the prevention and treatment of diseases with unmet medical needs.
|Category||Growth Capital Firm|
|PE ASSETS||3.0B USD|
Essex Woodlands Health Ventures is a growth equity and venture capital specialist investment firm focused on opportunities across the healthcare sector. Specific areas of interest include biotechnology, pharmaceuticals, medical devices, and healthcare services/IT. Historically, Essex invested primarily in early and later-stage situations; however, today the firm also makes growth capital investments between $20 - $60 million in companies valued between $50 - $250 million, as well as private investments in public entities (PIPEs). Essex Woodlands was formed in 1985 and offices in Palo Alto, California; New York City; Houston, Texas; Shanghai and London.
|Overall||13 of 52|
|Sector (Medical Products)||6 of 23|
|Type (Add-on Acquisition)||7 of 34|
|State (Pennsylvania)||2 of 7|
|Country (United States)||12 of 45|
|Year (2008)||4 of 5|
|Size (of disclosed)||19 of 22|
California, United States
LipoSonix is developing technology for noninvasive cosmetic surgery applications. LipoSonix was acquired by Medicis Pharmaceutical.
Dow Pharmaceutical Sciences
Petaluma, California, United States
Developer, manufacturer and marketer as well as formulator of topical therapies focused on the dermatology market.